DAWN vs REGN: Which Stock is Better?
Side-by-side comparison of Day One Biopharmaceuticals Inc and Regeneron Pharmaceuticals Inc in 2026
DAWN
Day One Biopharmaceuticals Inc
$12.11
REGN
Regeneron Pharmaceuticals Inc
$733.78
Key Metrics Comparison
| Metric | DAWN | REGN | Winner |
|---|---|---|---|
| Market Cap | $1.04B | $77.69B | REGN |
| P/E Ratio | N/A | 17.57 | REGN |
| EPS (TTM) | $N/A | $41.71 | REGN |
| Revenue Growth | -0.6% | 0.0% | REGN |
| Gross Margin | 89.4% | 45.8% | DAWN |
Analyze DAWN
Full quant analysis
Analyze REGN
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is DAWN or REGN a better investment?
Comparing DAWN and REGN: Day One Biopharmaceuticals Inc has a market cap of $1.04B while Regeneron Pharmaceuticals Inc has $77.69B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between DAWN and REGN?
DAWN (Day One Biopharmaceuticals Inc) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: DAWN or REGN?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: DAWN or REGN?
REGN has higher revenue growth at 0.0% vs -0.6% for DAWN.
Which company is more profitable: DAWN or REGN?
Day One Biopharmaceuticals Inc (DAWN) has higher gross margins at 89.4% compared to 45.8% for REGN.
Which is the larger company: DAWN or REGN?
Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $77.69B compared to $1.04B for DAWN.
Should I buy DAWN or REGN in 2026?
Both DAWN and REGN have investment merit. DAWN trades at $12.11 while REGN trades at $733.78. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between DAWN and REGN stock?
Key differences: Market Cap ($1.04B vs $77.69B), P/E Ratio (N/A vs 17.6x), Revenue Growth (-0.6% vs 0.0%), Gross Margin (89.4% vs 45.8%).